

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Paluck Thomas S</u>  (Last) (First) (Middle) 382 SPRINGFIELD AVENUE, SUITE 500  (Street) SUMMIT NJ 07901  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/31/2007	3. Issuer Name and Ticker or Trading Symbol <u>AVANT IMMUNOTHERAPEUTICS INC [ AVAN ]</u>		
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year)
				6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.001 per share	4,300,114	D <sup>(1)</sup>	
Common Stock, par value \$0.001 per share	130,000	I <sup>(1)</sup>	By wife
Common Stock, par value \$0.001 per share	3,202,232	I <sup>(2)(3)</sup>	By private investment accounts <sup>(1)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

**Explanation of Responses:**

- As of December 31, 2007 (the "Reporting Date"), Thomas S. Paluck held 1,000,000 shares of common stock, par value \$0.001 per share (the "Shares"), of AVANT Immunotherapeutics, Inc. (the "company"), which includes 230,000 Shares held in the name of Dorothy Paluck, Mr. Paluck's wife.
- In addition, as of the Reporting Date, TSP Capital Management Group, LLC ("TSP") managed one or more private investment accounts on behalf of various clients (the "Managed Accounts"), which owned in the aggregate 6,632,346 Shares. Mr. Paluck is the sole principal of TSP. In addition, Mr. Paluck possesses sole power to direct the disposition of the securities held by the Managed Accounts. Thus, as of the Reporting Date, for the purposes of Reg. Section 240.13d-3, Mr. Paluck may be deemed to beneficially own 7,632,346 Shares or 10.3% of the Shares issued and outstanding as of the Reporting Date. The reporting person hereby expressly disclaims membership in a "group" under the Securities Exchange Act of 1934 with respect to the securities reported herein, and this Form 3 shall not be deemed to be an admission that the reporting person is a member of such a group.
- The reporting person hereby expressly disclaims beneficial ownership of the securities reported herein, other than to the extent of his pecuniary interest therein, and this Form 3 shall not be deemed to be an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of the Securities Exchange Act of 1934 or for any other purpose.

/s/ Thomas S. Paluck 02/26/2008

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.